Previous 10 | Next 10 |
Sema4 press release (NASDAQ:SMFR): Q4 GAAP EPS of -$0.17. Revenue of $57.8M (-9.6% Y/Y). Total cash and cash equivalents were $400.6 million as of December 31, 2021. For further details see: Sema4 GAAP EPS of -$0.17, revenue of $57.8M
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiter...
ACHR, AGRO, ALT, ASLE, BRT, COUP, CVGW, DLO, ENZ, FINV, GTLB, HOFV, LIFE, LRFC, MHLD, MTN, NOAH, OTC:NWHUF, OPTT, PEI, SLGG, SMFR, WPRT, YALA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2022. Sema4 was ranked as ...
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the...
STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics , a phenomics-driven drug discovery company, today announced a strategic partnership to accelerate t...
STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: BTIG MedTech, Digital Health, Life S...
AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...
STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its Market Access team to drive increased market access for the company’s platform. The team’s key...
Technology is evolving faster than our brains can keep up. From wearable technology to smart homes to drones, everything we know, and love is being “disrupted” by the Internet of Things (IoT). Today a small company called GBT Technologies Inc. (OTC US: GTCH) develops A...
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Company Name:
SMFR Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...